The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma

Current Medical Research and Opinion

Volumn 24, Issue 3, 2008, Pages 879-894

  Murphy, Kevin ^a   Nelson, Harold ^b   Parasuraman, Bhash ^c   Boggs, Robert ^c   Miller, Christopher ^c   O'Dowd, Liza ^c  

^a Midwest Allergy and Asthma Clinic   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Asthma control; Health related quality of life; Inhaled corticosteroids; Long acting 2 adrenergic agonists; Patient satisfaction; Patient reported outcomes

Indexed keywords

BUDESONIDE; FLUTICASONE; FORMOTEROL; PLACEBO; SALMETEROL;

ADULT; AGED; AROUSAL; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRY POWDER; ELECTRONICS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT SATISFACTION; PHYSICIAN; POPULATION; POWDER INHALER; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SLEEP; STATISTICAL SIGNIFICANCE; SYMPTOM;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HEALTH SURVEYS; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; PATIENT SATISFACTION; PRESSURE; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 41149085572     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X273354     Document Type: Article

References (34)

1. National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma (full report 2007). Bethesda, MD: August 2007. NIH Publication No. 08-4051
2. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636-42
3. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002;19:182-91
4. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-24
5. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11
6. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392-97
7. Zetterström O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001;18:262-8
8. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000;161:527-34
9. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000;105:1108-16
10. Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs 2004;64:1597-618
11. Markham A, Jarvis B. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 2000;60:1207-33
12. Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005:CD005533
13. Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005;60:730-4
14. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention - updated 2007. [Accessed at www.ginasthma.org]
15. Juniper EF, Jenkins C, Price MJ, James MH. Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma. Am J Respir Med 2002;1:435-40
16. Draft Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Rockville, MD: Food and Drug Administration; 2006
17. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-9
18. van Schayck CP, Dompeling E, Rutten MP, et al. The influence of an inhaled steroid on quality of life in patients with asthma or COPD. Chest 1995;107:1199-205
19. Corren J, Korenblat P, Miller C, et al. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther 2007;29:823-43
20. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Resp Dis 1987;136:225-44
21. Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83
22. Juniper EF, Buist AS, Cox FM, et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999;115:1265-70
23. Bushnell DM, Martin ML, Parasuraman B. Electronic versus paper questionnaires: a further comparison in persons with asthma. J Asthma 2003;40:751-62
24. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81-7
25. Hays RD, Stewart AL. Sleep measures: definitions and issues. Measuring functioning and well-being. The medical outcomes study approach. In: Stewart AL, Ware JE, eds. Durham, NC: Duke University Press, 1992:235-59
26. Mathias SD, Warren EH, Colwell HH, Sung JC. A new treatment satisfaction measure for asthmatics: a validation study. Qual Life Res 2000;9:873-82
27. Westfall PH, Ho SY, Prillaman BA. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials. J Biopharm Stat 2001;11:125-38
28. Frison L, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med 1992;11:1685-1704
29. Juniper EF, Svensson K, O'Byrne PM, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 1999;14:1038-43
30. Bergmann KC, Lindemann L, Braun R, Steinkamp G. Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. Swiss Med Wkly 2004;134:50-8
31. Center for Drug Evaluation and Research. ADVAIR DISKUS (Fluticasone Propionate and Salmeterol Xinafoate) Inhalation Powder. Application number: 21-077. Available at: http://www.fda.gov/cder/foi/nda/2000/21077_AdvairDiskus. htm. [Last accessed March 2007]
32. Chuchalin AG, Svensson K, Stahl E, et al. A health-related quality-of-life comparison of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia. Respiration 2002;69:427-33
33. Noonan M, Rosenwasser LJ, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma. Drugs 2006;66:2235-54
34. Miller CJ, Senn S, Mezzanotte WS. Bronchodilation of formoterol administered with budesonide: device and formulation effects. Contemp Clin Trials 2007 Jun 7 [epub ahead of print: doi:10.1016/j.cct.2007.05.008]